Oteseconazole: An Advance in Treatment of Recurrent Vulvovaginal Candidiasis
Open accessAbstract
Recurrent vulvovaginal candidiasis (RVVC) has significant disease, financial and quality-of-life burdens, affects women from all strata of society worldwide, and lacks an approved therapeutic solution. Fluconazole emerged in 2004 as an antifungal for RVVC; it provides symptom control and has been accepted worldwide as a first-line treatment. Its limitations include the development of resistance and a high rate of vulvovaginal candidiasis recurrence after therapy cessation. There is now an improved treatment option on the horizon: oteseconazole - a novel, oral, selective fungal cytochrome P450 enzyme 51 inhibitor, designed to avoid off-target toxicities. In clinical studies to date, oteseconazole has demonstrated impressive efficacy, a positive tolerability profile and hope for a superior RVVC treatment option.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Oteseconazole has demonstrated potent antifungal activity against clinical isolates of Candida species, including those with reduced susceptibility to standard azole agents.
“It has demonstrated potent antifungal activity against clinical isolates of Candida species, including those with reduced susceptibility to standard azole agents. 30”
From Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis (2022) · cites this paper as [30]
For women with RVVC, oteseconazole may probably be a first-line drug due to its prevention of vaginal recolonization for a longer period than current treatment options, especially in women infected with C. glabrata and those with badly controlled diabetes mellitus.
“For women with RVVC, oteseconazole may probably be a first-line drug due to its prevention of vaginal recolonization for a longer period of time than current treatment options, especially in women infected with C. glabrata, as well as those with badly controlled diabetes mellitus in whom there is an impaired response to fluconazole [63].”
From Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods (2023) · cites this paper as [63]
The study authors showed that oteseconazole could prevent vaginal recolonization for up to 12 months.
“In addition, the study authors showed that oteseconazole could prevent vaginal recolonization for up to 12 months.”
From Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods (2023) · cites this paper as [63]
Sobel et al. in 2021 showed that oteseconazole achieves control of VVC symptoms up to 50% faster than fluconazole.
“In 2021, Sobel et al. showed that oteseconazole achieves control of VVC symptoms up to 50% faster than fluconazole [63].”
From Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods (2023) · cites this paper as [63]
Oteseconazole or ibrexafungerp seem to be effective in relapses of VVC.
“Although oteseconazole or ibrexafungerp seem to be effective in relapses, more clinical trials or treatment regimens for these drugs still need to be conducted.”
From Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods (2023) · cites this paper as [63]
Potent efficacy and safety data support the potential value of oteseconazole to treat both azole-sensitive and azole-resistant C. albicans and non-albicans strains in women who cannot be treated in other ways.
“Potent efficacy and safety data support the potential value of oteseconazole to treat both azole-sensitive and azole-resistant C. albicans and non-albicans strains in women who cannot be treated in other ways (Sobel and Nyirjesy, 2021; Sobel JD/Donders G et al., 2022).”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel and Nyirjesy, 2021
Cites
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · see citing works
Self-citationGlobal burden of recurrent vulvovaginal candidiasis: a systematic review
Denning, D. W., Kneale, M., Sobel, J. D., & Rautemaa-Richardson, R. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30103-8 · Cited by 639 · see citing works
Self-citationRecurrent vulvovaginal candidiasis
Sobel, J. D. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.06.067 · Cited by 502 · see citing works
Self-citationMaintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis
Sobel, J. D., Wiesenfeld, H. C., Martens, M., Danna, P., Hooton, T. M., Rompalo, A., Sperling, M., Livengood, C., Horowitz, B., Von Thron, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033114 · Cited by 487 · see citing works
Self-citationPharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 399 · see citing works
Vulvovaginal Candidiasis: A Current Understanding and Burning Questions
Willems, H. M. E., Ahmed, S. S., Liu, J., Xu, Z., & Peters, B. M. (2020) · Journal of Fungi · doi:10.3390/jof6010027 · Cited by 357 · see citing works
Interscience Conference on Antimicrobial Agents and Chemotherapy
(1961) · Folia Microbiologica · doi:10.1007/bf02864650 · Cited by 253 · see citing works
Recurrent Vulvovaginal Candidiasis
Sobel, J. D. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612043152305 · Cited by 219 · see citing works
Self-citationDesign and optimization of highly-selective fungal CYP51 inhibitors
Hoekstra, W. J., Garvey, E. P., Moore, W. R., Rafferty, S. W., Yates, C. M., & Schotzinger, R. J. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.05.068 · Cited by 195 · see citing works
Fluconazole-Resistant Candida albicans Vulvovaginitis
Marchaim, D., Lemanek, L., Bheemreddy, S., Kaye, K. S., & Sobel, J. D. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31827307b2 · Cited by 195 · see citing works
Self-citationRecurrent vulvovaginal candidiasis
Blostein, F., Levin-Sparenberg, E., Wagner, J., & Foxman, B. (2017) · Annals of Epidemiology · doi:10.1016/j.annepidem.2017.08.010 · Cited by 180 · see citing works
Warrilow, A. G. S., Hull, C. M., Parker, J. E., Garvey, E. P., Hoekstra, W. J., Moore, W. R., Schotzinger, R. J., Kelly, D. E., & Kelly, S. L. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03707-14 · Cited by 173 · see citing works
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species
Sobel, J. D., & Sobel, R. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1476490 · Cited by 168 · see citing works
Self-citationCytochrome P450 of Fungi: Primary Target for Azole Antifungal Agents
Yoshida, Y. (1988) · Current topics in medical mycology · doi:10.1007/978-1-4612-3730-3_11 · Cited by 143 · see citing works
Garvey, E. P., HOEKSTRA, W., Schotzinger, R. J., Sobel, J. D., Lilly, E. A., & Fidel, P. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00185-15 · Cited by 83 · see citing works
Self-citationBrand, S. R., Degenhardt, T. P., Person, K., Sobel, J. D., Nyirjesy, P., Schotzinger, R. J., & Tavakkol, A. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.03.001 · Cited by 78 · see citing works
Self-citationSchell, W. A., Jones, A. M., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., & Alexander, B. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01817-16 · Cited by 74 · see citing works
A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis
Brand, S. R., Sobel, J. D., Nyirjesy, P., Ghannoum, M. A., Schotzinger, R. J., & Degenhardt, T. P. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1204 · Cited by 61 · see citing works
Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models
Shubitz, L. F., Trinh, H. T., Galgiani, J. N., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00593-15 · Cited by 57 · see citing works
Collins, L. M., Moore, R., & Sobel, J. D. (2020) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000496 · Cited by 55 · see citing works
Self-citationOral Ibrexafungerp: An Investigational Agent for the Treatment of Vulvovaginal Candidiasis
Azie, N., Angulo, D., Dehn, B., & Sobel, J. D. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1791820 · Cited by 46 · see citing works
Self-citationCrouss, T., Sobel, J. D., Smith, K., & Nyirjesy, P. (2018) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000413 · Cited by 29 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods
Satora, M., Grunwald, A., Zaremba, B., Frankowska, K., Żak, K., Tarkowski, R., & Kułak, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165376 · Cited by 84 · see citing works
Donders, G., Sziller, I. O., Paavonen, J., Hay, P., de Seta, F., Bohbot, J. M., Kotarski, J., Vives, J. A., Szabo, B., Cepuliené, R., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.934353 · Cited by 82 · see citing works
Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis
Neal, C. M., & Martens, M. G. (2022) · SAGE Open Medicine · doi:10.1177/20503121221115201 · Cited by 56 · see citing works
- Authors
- Sobel, J. D., & Nyirjesy, P.
- Affiliations
- Wayne State University (US)
- Thomas Jefferson University (US)
- Corresponding author
- Sobel, Jack D
- Venue
- Future Microbiology
- Publisher
- Informa UK Limited
- Published
- 2021-11-16
- Volume
- 16
- Issue
- 18
- Pages
- 1453-1461
- ISSN
- 1746-0913 (ISSN-L)
- 1746-0921
- OpenAlex
- W3214098114
- Cited by
- 78
- References
- 22
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 14 · 2023: 28 · 2022: 15
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Future Microbiology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Mycovia Pharmaceuticals and Scynexis
- Mycovia Pharmaceuticals Inc.
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
- Keywords
- oteseconazole, recurrent vulvovaginal candidiasis, fluconazole, antifungal resistance, CYP51 inhibitors, oral antifungal therapy, treatment efficacy, drug tolerability, candidiasis recurrence
- MeSH terms
- Antifungal Agents, Candida albicans, Candidiasis, Vulvovaginal, Female, Humans, Recurrence, Fluconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
